FDA updates Zytiga label with OS results; FDA reviewers back Medicines Co. clot preventer;

> The FDA has approved a label update for Johnson & Johnson's ($JNJ) Zytiga that includes overall survival results in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Release

> FDA reviewers have recommended that the agency approve The Medicines Company's ($MDCO) once-rejected blood clot preventer. Report

> European payers are still the most important targets of health economics and outcomes research when it comes to getting a product onto formularies, new research shows. Release

> Roche ($RHHBY) aims to have an immunotherapy cancer drug in 11 late-stage trials by the end of the year. Report

> Specialty dermatology drugmaker Cipher Pharmaceuticals has acquired Innocutis Holdings, the licensee of Sitavig, in the U.S. Release

> IBM ($IBM) is growing its presence in healthcare with the rollout of the Watson Health unit, extending its partnership with Apple and inking deals with Johnson & Johnson and Medtronic ($MDT). More

And Finally... AstraZeneca ($AZN), looking to bring patient-centric evidence into drug discovery and development, has signed a 5-year deal with PatientsLikeMe for access to the network's 325,000-plus members. More

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.